News from the healthcare data industry
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and...
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December...
December 01, 2021 09:46 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research &...
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather...
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a...
Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working...
November 18, 2021 10:46 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations...
Tempus Labs Inc., a precision medicine startup led by a Groupon Inc. co-founder, is exploring a U.S. initial public offering, according to people with knowledge of the matter. The Chicago-based company is...
Tempus’ platform brings research to life with predictive algorithms that screen cancer patients for mutations in the DPYD gene Tempus, a leader in artificial intelligence and precision medicine, today announced...
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA,...